Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sorafenib tosylate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 147 for your search:
Start Over
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2011PTAHCC, NCT01409499
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TACE-Sorafenib, NCT01833299
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-213, NCT01849588
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: INT 80/09, NCT01387503
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: OP2, NCT01747642
Sorafenib Chemoembolization Evaluation Controlled Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: XHDD-001, NCT01906216
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: QCH20130823, NCT01932385
The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HCC201408, NCT02220088
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021
Sorafenib Long Term Extension Program (STEP)
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12311, 2007-002604-17, NCT00625378
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01989, CDR0000659348, CALGB 80802, U10CA180821, U10CA031946, NCT01015833
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AHCC06, NCT01135056
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: SILIUS Phase III trial, NCT01214343
Caphosol in Oral Mucositis Due to Targeted Therapy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Esperanz-002, NCT01265810
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: BOOST, EudraCT number 2009-013870-42, NCT01405573
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-103, NCT01556490
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 1112, NCI-2012-02057, U10CA021661, NCT01730937
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-304, NCT01761266
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: STAH Korea Trial, NCT01829035
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-104, 2012-005375-14, NCT01887717
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00264, A091105, U10CA031946, NCT02066181
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SWHB008, NCT02187081
Start Over